Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06137157 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
A Phase 1 study of Netherton Syndrome, sponsored by Azitra.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT06137157: Recruiting Phase 1 study of Netherton Syndrome, sponsored by Azitra.
NCT06137157 is a Phase 1 study of Netherton Syndrome that is actively recruiting participants, run by Azitra. The registered enrollment target is 12 participants, below the 27-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06137157, a Phase 1 study of Netherton Syndrome, is actively recruiting participants, sponsored by Azitra.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.
Primary Outcome
Incidence, severity, seriousness and relatedness of all treatment-emergent adverse events
Conditions Studied
Interventions
- DRUG ATR12-351
Study Locations (2)
California
- Stanford University - Palo Alto
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 1 |
What NCT06137157 shows while recruiting
NCT06137157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 27-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Netherton Syndrome appearing as the primary indexed condition, and to 1 intervention - of which ATR12-351 is the first listed.
NCT06137157 reports a single indexed study location in California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06137157 about?
NCT06137157 is a clinical study titled "Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome". The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to...
What is the current status of trial NCT06137157?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-06-19. Estimated completion is 2026-08-01.
What conditions does trial NCT06137157 study?
This clinical trial studies the following conditions: Netherton Syndrome.
What interventions are being tested in trial NCT06137157?
The interventions under investigation include: ATR12-351 (DRUG).
Who is sponsoring clinical trial NCT06137157?
This trial is sponsored by Azitra, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06137157 being conducted?
This trial has 2 study locations across California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Netherton Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
RECRUITING · Phase 1
-
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
COMPLETED · Phase 1
-
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
RECRUITING · Phase 2
-
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI